Erik Istre, MD
Neurology · Queensbury, NYNPI 1912228669
Payments from drug & device makers
Across 367 payments — averaging $61.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- EMD Serono, Inc.$1K
- Sanofi$689
- Genentech USA, Inc.$517
- Axsome Therapeutics, Inc.$431
- Biogen$389
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$12,33855%
- Food & beverage$10,00445%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 210 | $16,879 |
| EMD Serono, Inc. | 19 | $1,238 |
| Sanofi | 8 | $689 |
| Genentech USA, Inc. | 9 | $517 |
| Axsome Therapeutics, Inc. | 9 | $431 |
| Biogen | 19 | $389 |
| SK Life Science, Inc. | 5 | $353 |
| Novartis | 30 | $304 |
| E.r. Squibb & Sons, L.L.C. | 3 | $259 |
| Amgen(2 entities) | 3 | $176 |
| Bristol Myers Squibb | 8 | $164 |
| Johnson & Johnson | 3 | $163 |
| Pfizer | 7 | $116 |
| Neurocrine Biosciences, Inc. | 3 | $86 |
| Scilex Pharmaceuticals Inc. | 5 | $77 |
| AstraZeneca | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Livanova USA, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $43 |
| Lundbeck LLC | 1 | $40 |
| TG Therapeutics, Inc. | 2 | $40 |
| Harmony Biosciences LLC | 1 | $37 |
| UCB, Inc. | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Impel Pharmaceuticals LLC | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,385 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 200 | $286,206 |
| TecfideraDimethyl Fumarate | 15 | $205,846 |
| BriviactBrivaracetam | 83 | $182,275 |
| AmpyraDalfampridine | 33 | $164,913 |
| Nurtec OdtRimegepant Sulfate | 105 | $142,372 |
| GilenyaFingolimod Hcl | 19 | $127,185 |
| UbrelvyUbrogepant | 97 | $125,171 |
| Kesimpta PenOfatumumab | 14 | $117,845 |
| MayzentSiponimod | 11 | $99,652 |
| AptiomEslicarbazepine Acetate | 79 | $86,400 |
| CopaxoneGlatiramer Acetate | 14 | $85,692 |
| Dalfampridine ErDalfampridine | 102 | $76,524 |
| NuplazidPimavanserin Tartrate | 12 | $63,220 |
| QuliptaAtogepant | 41 | $56,480 |
| NuedextaDextromethorphan Hbr/Quinidine | 31 | $52,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $353 | $286,206200 claims |
| NovartisGilenya, Mayzent | $304 | $226,83730 claims |
| BiogenTecfidera | $389 | $205,84615 claims |
| UCB, Inc.Briviact, Vimpat | $26 | $197,27395 claims |
| AbbVieUbrelvy, Qulipta | $16,879 | $181,651138 claims |
| PfizerNurtec Odt | $116 | $142,372105 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $18 | $86,40079 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $15 | $85,69214 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $15 | $52,62231 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $20 | $34,37812 claims |
| Axsome Therapeutics, Inc.Auvelity | $431 | $34,34931 claims |
| Eisai Inc.Fycompa | $21 | $16,88213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.
Other neurology in Queensbury
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
- Krupa PandeyAlbany$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.